Want to see BRNS full AI Analyst Report?
BRNS Stock Chart & Stats
$0.60
>-$0.01(-0.33%)
At close: 4:00 PM EDT
$0.60
>-$0.01(-0.33%)
Day’s Range― - ―
52-Week Range$0.51 - $1.83
Previous CloseN/A
Volume5.81K
Average Volume (3M)124.73K
Market Cap
$25.40M
Enterprise Value-$22.31
Total Cash (Recent Filing)$59.30M
Total Debt (Recent Filing)$10.29M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Nov 05, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet LeverageRelatively low leverage limits interest and refinancing pressure, giving the development-stage company more financial flexibility than a heavily indebted peer. This supports continued investment in clinical programs, although it does not eliminate the need for future capital.
Scheme Approval MilestoneOverwhelming shareholder approval removes a major procedural obstacle and provides greater certainty around the proposed transaction structure. Completion still depends on remaining legal and regulatory steps, but the milestone can support strategic continuity and counterparties.
Focused Immunotherapy PlatformA focused immune-based development strategy can concentrate scarce resources around targeted clinical programs and combination opportunities. The approach gives the business a defined scientific direction, though its commercial value remains dependent on clinical validation.
Bears Say
No Current Revenue BaseThe absence of recurring revenue leaves the company dependent on clinical progress and external financing rather than operating income. Large ongoing losses also reduce earnings visibility, making future performance highly dependent on successful development and commercialization.
Persistent Cash BurnContinued cash outflows mean the company must fund research and operations without internally generated cash. This creates recurring financing needs and exposes shareholders to potential dilution or program reductions if available capital becomes insufficient.
Listing Compliance RiskThe extension preserves the listing temporarily but confirms an unresolved compliance issue and continued share-price pressure. Failure to regain compliance could restrict market access, increase execution uncertainty, and complicate future capital-raising efforts.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $1.83 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $25.40M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Aug 06, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.02.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.25.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -0.877%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
BRNS Stock 12 Month Forecast
Average Price Target
$6.00
▲(900.00% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
21.57% Other Institutional Investors
78.40% Public Companies and
Individual Investors